Tau-Aggregation Inhibiting Compounds for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease are inadequate, as they only provide symptomatic relief without addressing the underlying molecular mechanisms of tau and alpha-synuclein pathologies, leading to ongoing neuronal degeneration and lack of effective preventive measures.
Innovation Solution
Development of novel compounds that inhibit tau-aggregation induced toxicity, specifically designed to target and prevent neurodegenerative disorders by stabilizing cellular integrity and reducing neuronal death, which can be used alone or in combination with other active ingredients for therapeutic and preventive applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative disorders, then symptomatic relief is provided, but the underlying molecular mechanisms of tau and alpha-synuclein pathologies are not addressed, leading to ongoing neuronal degeneration
Solution Approach 1:
The patent applies preliminary anti-action by developing compounds that prevent tau aggregation and alpha-synuclein pathology before neuronal degeneration occurs. The compounds (I) and (Ia) are designed to inhibit the formation of toxic tau aggregates and stabilize cellular integrity, acting preemptively against the disease mechanism rather than merely treating symptoms after damage has occurred.
Solution Approach 2:
The patent converts the harmful aggregation process into a beneficial target for intervention. By identifying specific molecular mechanisms of tau aggregation and alpha-synuclein pathology, the invention creates compounds that specifically bind to and inhibit these harmful processes, transforming the understanding of the disease mechanism into a therapeutic advantage through targeted molecular intervention.
2Reliability
If novel compounds are developed to inhibit tau-aggregation toxicity, then neuronal death is reduced and disease progression is retarded, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the compounds to optimize their ability to inhibit tau aggregation. The general formula (I) with various substituents (R1-R6, E, n, X1-X5, L, B, m, R8) allows systematic variation of molecular parameters to enhance binding affinity, selectivity, and pharmacological properties while maintaining the core mechanism of action against tau pathology.
Data Source
AI summary
This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.